

Cancer Council Australia

ABN 91 130 793 725

Financial Report

for the year ended 30 June 2016

About Cancer Council Australia

As Australia's leading national non-government cancer control* organisation, Cancer Council Australia advises the Australian Government and other bodies on practices and policies to help prevent, detect and treat cancer. We also advocate for the rights of people affected by cancer for best treatment and supportive care.

Our vision

Minimise the threat of cancer to Australians, through successful prevention, best treatment and support.

Our mission

To lead a cohesive approach to reduce the impact of cancer by building capacity and effectiveness in the cancer community sector.

Our activities

Cancer Council Australia works with the eight State and Territory Cancer Councils which are its members, to:

- undertake and fund cancer research
- prevent and control cancer
- provide information and support for people affected by cancer.

Our history

Cancer Council Australia commenced in 1961 as the *Australian Cancer Society*, an incorporated association, when the six state Cancer Councils – which then varied in name and brand – agreed to establish a federal body to promote cancer control at the national level. Cancer organisations in the ACT and the Northern Territory were subsequently formed and signed on as members of the Society.

While State and Territory Cancer Councils continued to play the predominant role in research, public health, patient support and education programs, the federal body's primary role was to develop independent national cancer control policy – albeit on a comparatively modest scale.

In 1997, the eight jurisdictional members agreed to expand the Society, adopting the trading name of *The Cancer Council Australia* and appointing an expert Chief Executive Officer, Professor Alan Coates, to lead the push for improved national cancer control policy and build the Cancer Council brand and profile. Specialist staff in communications, advocacy, business management, marketing and other professional roles were recruited to promote the organisation's mission.

Over the ensuing decade, State and Territory Members uniformly adopted the name Cancer Council and together took on the image of the daffodil, a global symbol of hope, as our common logo.

In 2008, the organisation migrated from being registered as an Incorporated Association to a Company Limited by Guarantee, and formalised its registered name as *Cancer Council Australia*.

Cancer Council Australia is also allied with the *Clinical Oncology Society of Australia*, which provides advice on medical and scientific issues, and is a member of the *Australian Chronic Disease Prevention Alliance*, as well as global collaborations such as the *Union for International Cancer Control*.

Over its 53-year history, Cancer Council Australia has transformed from a small secretariat to a strong federal body that has become Australia's leading independent authority on cancer control.

Cancer Council Australia seeks to engage all Australians in our work to reduce the impact of cancer in Australia through advocacy, research, education and support.

*Cancer control refers to actions to reduce the impact of cancer on people including: reducing cancer risk and incidence; improving early detection and treatment; and improving care and support for people affected by cancer.

Cancer Council Australia

(A Company limited by guarantee)

Corporate Information

ABN 91 130 793 725

Patron

Sir Gustav Nossal AC CBE

Directors as at 30 June 2016

The Hon. Nicola Roxon
Ms Annette Burke
Professor Judith Dwyer
Ms Jane Fenton AM
Mr Graham Gibson
Dr Anita Green
Ms Rosanna Martinello
Associate Professor Jeremy Millar
Professor George Yeoh
Mr Stephen Foster
Professor Meinir Krishnasamy
Mr Mark Phillips
Mr Hugh Harley

Company Secretary

Ms Susan Bennett

Chief Executive Officer

Professor Sanchia Aranda

**Registered office and
principal place of business**

Level 14
477 Pitt Street
Sydney NSW 2000

Company contact details

GPO Box 4708
Sydney NSW 2001

P: +61 (0)2 8063 4100

F: +61 (0)2 8063 4101

E: info@cancer.org.au

W: www.cancer.org.au

Auditors

BDO East Coast Partnership
Level 11
1 Margaret Street
Sydney NSW 2000

Cancer Council Australia (ABN 91 130 793 725)

Directors' Report

30 June 2016

The Directors present their report on Cancer Council Australia ("the Company") for the year ended 30 June 2016.

Objectives consistent with the Vision and Mission the Company's long-term objectives are to:

- Reduce the burden of cancer on the community
- Drive change by providing evidence-based advice and advocating for action and policy change to:
 - Reduce cancer risk and incidence
 - Improve prevention and early detection
 - Improve cancer treatment and management
 - Improve care and support for people affected by cancer
- Prioritise and support quality research
- Share information about cancer to increase community awareness, understanding and action
- Increase income and cost effectiveness through national coordination of fundraising events and our common services and activities
- Engage and collaborate with government and non-government cancer agencies at the national and international level to increase the efficacy of cancer control initiatives
- Produce cancer management guidelines to promote evidence-based clinical practice using innovative update and dissemination strategies such as the wiki platform

In pursuing these objectives the Company's primary short-term objectives over the reporting period were:

- Public health advocacy - focused on the National Bowel Cancer Screening Program, National Tobacco Strategy, strengthened obesity control policies, skin cancer prevention and advancing the agenda for occupational cancers
- Clinical practice – Develop and promote clinical practice guidelines on our wiki platform, and online educational resources for health professionals
- Fundraising – Increase corporate partnerships, improve event participant retention and engage more Australians through increased brand awareness

A Year In Transition

This financial year has been marked by a series of transitions. In May 2015 the Members signed off on the first of a series of changes to the Company's constitution. The hallmark of the changes initially agreed was the appointment of an independent Chair to the Board of Directors. The Honourable Nicola Roxon was appointed to the role in July 2015. A new CEO for the Company was also appointed in August 2015, Professor Sanchia Aranda.

These two appointments created significant opportunity for renewal of the Company and mark a period of considerable change. Further changes to the Company's constitution have been developed over the 2015-2016 period with the aim of being approved by the end of 2016. These changes seek to modernise the constitution, clarify terms of office for Directors and seek to ensure compliance with regulations governing charities and companies. The changes will also see the adoption of refreshed Objects to ensure the Company is best positioned to support the work of its Members and to make a stronger impact on cancer control in Australia.

The process to develop a new strategic plan has commenced that will continue to strengthen the place of the Company and its Members in the national landscape as an evidence-based cancer control entity. The new strategic plan will aim to continue to build the Company's credibility and reputation as the leading national non-Government cancer control body and to strengthen the Company's capacity to meet new challenges in cancer control.

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Principal activities

The principal activities of Cancer Council Australia during the year were focused on furthering both our short- and long-term objectives, referenced above. More detail on the achievements against these objectives are detailed in the 2015-16 Annual Review.

Review of financial operations and results of Cancer Council Australia

The total income for the financial year ended 30 June 2016 was \$10,938,059. In the same period, expenditure was \$10,808,249 leaving a surplus of \$129,810. The level of spending for the Company varies from year to year as the range of activities to support our Members, and the costs associated with them, also vary. This expenditure includes our investment in health strategies and activities to reduce the impact of cancer, more details of which are outlined in the Driving Change and Sharing Information sections of Cancer Council Australia 2015-16 Annual Review.

Matters Subsequent to the end of Financial Year

The Directors are not aware of any significant events have occurred since the end of the reporting period which would impact on the financial position of the Company disclosed in the balance sheet as at 30 June 2016 or on the results and cash flows of the Company for the year ended on that date.

Indemnity and insurance of officers

The Company has indemnified the Directors and Executives of the Company for costs incurred, in their capacity as a Director or Executive, for which they may be held personally liable, except where there is a lack of good faith.

During the financial year, the Company paid a premium of \$8,450 in respect of a contract to insure the Directors and Executives of the Company against a liability to the extent permitted by the Corporations Act 2001.

Indemnity and insurance of auditor

The Company has not, during or since the end of the financial year, indemnified or agreed to indemnify the auditor of the Company or any related entity against a liability incurred by the auditor.

During the financial year, the Company has not paid a premium in respect of a contract to insure the auditor of the Company or any related entity.

Proceedings on behalf of the Company

No person has applied to the Court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Company, or to intervene in any proceedings to which the Company is a party for the purpose of taking responsibility on behalf of the Company for all or part of those proceedings.

Environmental Regulation

The Company is not subject to any significant environment regulations.

Dividends

The Company does not permit any dividends and therefore no dividends have been paid or declared.

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Directors

The names of the Directors of the Company in office during or since the end of the year are:

Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Audit & Risk Committee
				Attended / Eligible to attend			
<p>The Hon. Nicola Roxon The Hon. Nicola Roxon is a well-respected figure in Australian public health. As Australia's Health Minister from 2007 – 2011, Ms Roxon held responsibility for the Federal Government's \$64 billion health portfolio, and led key public health initiatives, including the introduction of Australia's world-first plain packaging tobacco legislation. In 2013 she was appointed Australia's first female Attorney General. Since her retirement from parliament in 2013, Ms Roxon has developed a career as a non-executive director. She is currently a Director of BUPA ANZ, Chairman of the Accounting Professional and Ethical Standards Board and Chair of the Sir Zelman Cowen Centre at the Victoria University's College of Law and Justice.</p>	<p>Board Chair, Executive Committee Chair, Member Governance Committee and Finance, Audit & Risk Committee (until 8 March 2016)</p>	17 June 2015	-	4/4	4/4	9/9	1/3
<p>Mr Stephen Foster CFP, Dip Financial Planning President of Cancer Council Tasmania, Mr Foster has been a member of Cancer Council Tasmania's Board for 16 years. He is a certified financial planner and partner in a financial planning business. Mr Foster has a strong blend and understanding of private and public administration, having worked with the Department of Health and Human Services and with Treasury and Finance. Mr Foster was also a qualified radiographer.</p>	<p>Director, Finance, Audit & Risk Committee Chair (from 8 March 2016), Member Executive Committee (from 8 March 2016)</p>	3 Sept 2015		3/3	0/1		1/1
<p>Ms Jane Fenton AM, FAICD, FPRIA, LL.B (Hons) Ms Fenton was the founder of public relations and marketing communications consultancy, Fenton Communications. She is Chair of the Queen Victoria Women's Centre, Deputy Chair of the Queen Victoria Market Pty Ltd, an MCG Trustee, immediate past Chair of VicHealth, a former Board Member of the Murdoch Children's Research Institute and a Life Governor of Very Special Kids. Ms Fenton is a Telstra Business Women's Award winner and received an Order of Australia Medal (AM) for service to the community, particularly through support of a range of health, medical research, youth and women's groups.</p>	<p>Deputy Chair, Member Executive Committee, Governance Committee (until 8 March 2016) and Finance, Audit & Risk Committee (from 8 March 2016)</p>	11 May 2012	-	4/4	4/4	7/8	1/1
<p>Ms Christine Brill JP, Grad Cert Mgt, Grad Dip Emp Rel, Master HRM, CAE, FSAE, AFACHSM, MAICD Ms Brill is a Director of Cancer Council ACT and been President of Cancer Council ACT since 2008. Ms Brill was the CEO and company secretary of the Australian Medical Association (ACT) Limited (until 31 July 2015) and Director of AMA Member Services (until November 2015). Ms Brill is a part time employee of the Australian Medical Association (ACT) Limited from November 2015 and has 30 years' experience in not-for-profits and community organisations.</p>	<p>Director, Member Governance Committee (until May 2016) and Finance, Audit & Risk Committee (until May 2016)</p>	4 Dec 2009	24 May 2016	3/4		4/9	2/5 'resigned FARC 3/5/2016

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Audit & Risk Committee
				Attended / Eligible to attend			
<p>Ms Annette Burke BA Hons, Dip Ed, MEd, MBA, ARLP Fellow (from November 2014)</p> <p>Ms Burke is a Director of the Board of Cancer Council NT, Chair of the Top End Health Board and Fellow of the Australian Rural Leadership Foundation. Having worked for the Abu Dhabi Government as Curriculum Manager at the Centre of Excellence and Director of Executive Education at the Abu Dhabi Chamber of Commerce, Ms Burke negotiated the first ever partnership with five of the world's leading education institutions – Oxford, Cambridge, Harvard, London Business School, Singapore Civil Service College and the National School of Government UK. Ms Burke was Mayor of Palmerston City Council from 1997 to 2007. She has post-graduate qualifications in education, international relationships and negotiations, and business administration.</p>	Director, Member Finance, Audit and Risk Committee (from 8 March 2016)	7 Nov 2014	-	2/4			1/1
<p>Professor Judith Dwyer Ph D, MBA, BA, FAICD, FCHSM</p> <p>Professor Dwyer is a health care management academic at the Flinders University School of Medicine, and a former CEO of Southern Health Care Network in Melbourne, and of Flinders Medical Centre in Adelaide, having worked in the Australian health system for more than 20 years. She was recently awarded the Sidney Sax Medal for her life-long contribution to the health system. She conducts research focused on health system governance and design with a focus on Aboriginal health policy and services, consults to government and other clients on related topics, and teaches in the Flinders' Masters of Health Administration. She is the lead author of the popular textbook Project Management in Health and Community Services.</p>	Director, Governance Committee Chair (from 8 March 2016) and Member Executive Committee	17 Oct 2013		4/4	4/4	8/9	
<p>Ms Sandra French AM</p> <p>In 1990, Mrs French became the first female elected Mayor of Burnie City Council. She was inducted to the Tasmanian Honour Roll of Women in 2009 for her service to the community and received an AM in 2010. Mrs French was the Founder for the Burnie Youth Council and the Youth Making Changes Around Burnie. She has been Tasmanian State President of the Australian Local Government Women's Association (1987-1990) and National President (1988-1990). She is a Local Government Association of Tasmania representative on the State Library Advisory Board and The Heritage Council, and chairs the Burnie Regional Art Gallery Advisory Committee.</p>	Director	22 Nov 2013	3 Sep 2015	1/1			
<p>Mr Graham Gibson QC, BA, LLB(Hons)(Old)</p> <p>Mr Gibson is Chairman, Cancer Council Queensland. He is a practising barrister and was appointed Queens Counsel in 1989.</p>	Director, Member Governance Committee	24 Apr 2008	-	2/4		5/9	
<p>Dr Anita Green MBBS, MSpMed, FRACGP, FASMF, FAICD</p> <p>Dr Green is a Director of Cancer Council Queensland, Deputy Chair of the Metro North Brisbane Primary Health Network and a member of the RACGP Queensland Advisory Board. She works at the University of Queensland Health Service as a General Practitioner, is a Visiting Medical Officer at The Prince Charles Hospital Heart Lung Institute and Chief Medical Officer for the 2018 Gold Coast Commonwealth Games. Dr Green is an experienced medical educator, with an appointment as a part time Senior Lecturer with the University of Queensland School of Human Movement and Nutrition Sciences.</p>	Director	3 Feb 2014		3/4			

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Audit & Risk Committee
				Attended / Eligible to attend			
<p>Mr Bruce Hodgkinson SC Mr Hodgkinson was Chair of Cancer Council NSW until December 2015 and has been a practising barrister at the Sydney Bar since the early 1980s. He was appointed Senior Counsel in 2001, is the head of Denman Chambers and continues to practise extensively in the field of work health and safety, coronial and regulatory inquiries and sports law. He is also the Chair of the Rugby Union Players Association.</p>	Director, Governance Committee Chair (until 8 March 2016)	24 Apr 2008	8 March 2016	3/3		7/8	
<p>Professor Meinir Krishnasamy BA, RN, DipN, MSc, Ph.D Professor Krishnasamy is President of the Clinical Oncology Society of Australia. She is Chair in Cancer Nursing at the University of Melbourne and Honorary Principal Research Fellow in the Department of Cancer Experiences Research at the Peter MacCallum Cancer Centre, in Melbourne. She is a past President of the Cancer Nurses Society of Australia.</p>	Director	7 Aug 2015	-	4/4			
<p>Ms Rosanna Martinello BCom, FAICD Ms Martinello is the consumer representative on Cancer Council Australia's Board. She brings to the Board direct consumer experience as a cancer survivor, carer and advocate and is a consumer representative on the COAG National Cancer Expert Reference Group. Ms Martinello also brings extensive board and business experience.</p>	Director, Member Governance Committee (from 8 March 2016)	13 May 2010	-	4/4		1/1	
<p>Associate Professor Jeremy Millar BMedSci MB ChB FRANZCR FChRMed Associate Professor Millar is the Director of Radiation Oncology at Alfred Health in Melbourne, where he also specialises in genito-urinary cancers. He has adjunct academic appointments at Monash University - where he works in cancer clinical quality registries - and at RMIT University, where he has physics research interests. He is Chair of the Clinical Network of Cancer Council of Victoria, and a non-Executive Director of the Cancer Council Victoria member of Cancer Council Victoria's Executive Committee (Board). He has previously been Medical Director of the Southern Melbourne Integrated Cancer Service.</p>	Director	22 May 2015	-	3/4			
<p>Associate Professor Sandro Porceddu MBBS (Hons), FRANZCR, MD Associate Professor Porceddu is the immediate past President of the Clinical Oncological Society of Australia. He is also President of the Trans Tasman Radiation Oncology Group (TROG), former President of the Australian Sarcoma Group and former Chair of the TROG Trials Scientific Committee. Associate Prof. Porceddu is a full-time Senior Radiation Oncologist at the Princess Alexandra Hospital, Brisbane, specialising in head and neck cancers.</p>	Director	1 Mar 2013	7 Aug 2015	0/1			
<p>Mr Stephen Roberts BBus Finance and Accounting (UTS), MBA (Insead), GAICD Mr Roberts is a member of the Board of Cancer Council NSW and Social Ventures Australia Leadership Council. Professionally, he is an independent company director. He is Chair of Cryosite Ltd, Growth Farms Pty Ltd, Pretium Partners and was Senior Partner and Regional Business Leader of Asia Pacific for Mercer Investments. He brings extensive business and management experience to the Board. Mr Roberts is trained as a chartered accountant, and is also Chair of the POSH Committee, which engages in fundraising activities for Cancer Council NSW.</p>	Director, Finance, Audit & Risk Committee Chair (until 8 March 2016), Member Executive Committee (until 8 March 2016)	6 Nov 2009	8 Mar 2016	3/3	2/3		4/4

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Name, Qualifications and Experience	Role	Date Joined	Date Ceased	Board	Executive Committee	Governance Committee	Finance, Audit & Risk Committee
				Attended / Eligible to attend			
<p>Professor George Yeoh Professor Yeoh served on the Research Grants Committee of Cancer Council WA from 1999 to 2009, the last eight years of which he was Chair. In 2009, he joined the Board of Cancer Council WA and was appointed President in 2014. He is a Senior Honorary Research Fellow in the School of Chemistry and Biochemistry. Professor Yeoh undertakes research at the University of WA and the Harry Perkins Institute of Medical Research. He has had a long-term interest in liver development and cancer. He is a Board member of the Institute for Respiratory Health, Deputy Director of the UWA Centre for Cell Therapy and Regenerative Medicine and a member of the National Health and Medical Research Council's Translational Research Faculty. He is a member of the Cancer Australia Advisory Council.</p>	Director	11 Dec 2013		2/4			
<p>Mr Mark Phillips Mark Phillips joined the board of Cancer Council Australia in May 2016. He is also Chairman of Cancer Council NSW. Mark has over 35 years' experience working in the business and not-for-profit sectors. His other board roles currently include being Executive Chairman of Remagen Capital Partners, a funds management and advisory business, chairman of the Advisory Board of the Banna Property Group, and a non-executive director of listed company, CSG Ltd, of General Reinsurance Australia, a member of the Berkshire Hathaway Group, and of Santa Sabina College. He is also an adviser to Opportunity International Australia, a microfinance charity. Earlier in his career, Mark spent over 20 years with the Commonwealth Bank of Australia in a variety of senior roles, and then became the Managing Director of companies listed on the Australian Stock Exchange. Mark has both a Bachelor and a Masters of Commerce from the University of NSW.</p>	Director, Member Governance Committee (from 24 May 2016)	24 May 2016		1/1			
<p>Mr Hugh Harley Hugh Harley is a financial services professional, having held senior executive and non-executive roles in the banking sector, and now is a partner in professional services. He currently leads PwC's Global Financial Services practice across the developing world, including Asia-Pacific, Africa, South America, and the Middle East. Previously he held senior roles in Commonwealth Bank, including head of Retail Banking and of Group Strategy, and was Chairman of the Audit Committee of ING Bank Australia. Hugh is also Adjunct Professor at the Sydney University Business School, with a particular teaching focus on the current implications of economic history. Hugh has honours degrees in Economics and Law from the University of Sydney and an M.Phil in Economics from the University of Cambridge. Hugh has previously held Chairman, Treasurer and Board positions in a variety of not-for-profit organisations, across professional services, education, child welfare, and charitable sectors.</p>	Director, Member Finance, Audit and Risk Committee (from 24 May 2016)	24 May 2016		1/1			

Directors are appointed on an honorary basis and as a result do not receive any remuneration either directly or indirectly from the Company.

Cancer Council Australia (ABN 91 130 793 725)
Directors' Report (cont'd)
30 June 2016

Chief Executive Officer

Professor Sanchia Aranda was appointed as the CEO to the Company on 3 August 2015.

Prior to that date Ms Catherine Sullivan had been Acting CEO.

Company Secretary

Susan Bennett LLM (Hons), MBA, GAICD was appointed Company Secretary in September 2014.

Contributions on winding up

In the event of the Company being wound up, ordinary Members are required to contribute a maximum of \$10 each.

Auditor's Independence Declaration


A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on the following page.

This report is made in accordance with a resolution of Directors, pursuant to section 298(2)(a) of the Corporations Act 2001.

On behalf of the Directors



The Hon. Nicola Roxon
Chair



Mr Hugh Harley
Director

Sydney
4 October 2016



Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

DECLARATION OF INDEPENDENCE BY PAUL CHEESEMAN TO THE DIRECTORS OF CANCER COUNCIL AUSTRALIA

As lead auditor of Cancer Council Australia for the year ended 30 June 2016, I declare that, to the best of my knowledge and belief, there have been no contraventions of any applicable code of professional conduct in relation to the audit.

A handwritten signature in black ink, appearing to read 'P. Cheeseman', is written over a light blue horizontal line.

Paul Cheeseman
Partner

BDO East Coast Partnership

Sydney, 4 October 2016

Cancer Council Australia (ABN 91 130 793 725)
Statement of Profit or Loss and Other Comprehensive Income
For the year ended 30 June 2016

	Note	2016	2015
		\$	\$
Member body subscriptions	1(d)(ii), 4	8,605,099	8,399,632
Interest income	1(d)(vi), 4	180,412	212,632
Central marketing fund income	1(d)(v), 4	729,601	714,051
Other revenue	4	1,422,947	1,572,919
Administration expenses		<u>(349,085)</u>	<u>(385,770)</u>
Marketing expenses		(2,180,940)	(1,923,481)
Central marketing fund expenses	1(d)(v)	(729,601)	(714,051)
Occupancy expenses		(397,299)	(379,086)
Depreciation expense		(126,299)	(178,814)
Priority Driven Research Grants		(499,241)	(498,132)
Other grants and support expenses		(1,052,712)	(1,197,789)
Employee expenses		(4,027,109)	(3,736,304)
Superannuation expense		(351,986)	(336,385)
Special project expenses		(541,087)	(617,288)
Other expenses		(552,890)	(357,023)
Surplus before income tax expense		<u>129,810</u>	<u>575,111</u>
Income tax expense	1(g)	-	-
Net surplus after income tax expense for the year attributable to the Members of Cancer Council Australia		<u>129,810</u>	<u>575,111</u>
Other Comprehensive Income for the year, net of tax		<u>-</u>	<u>-</u>
Total Comprehensive Income for the year attributable to the Members of Cancer Council Australia		<u><u>129,810</u></u>	<u><u>575,111</u></u>

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of Financial Position
As at 30 June 2016

	Note	2016	2015
		<u>\$</u>	<u>\$</u>
ASSETS			
Current Assets			
Cash & cash equivalents	5	4,447,444	3,617,313
Trade & other receivables	6	9,513,302	3,085,770
Other current assets	7	5,303,557	5,307,185
Total Current Assets		<u>19,264,303</u>	<u>12,010,268</u>
Non-Current Assets			
Plant & equipment	8	483,632	569,358
Total Non-Current Assets		<u>483,632</u>	<u>569,358</u>
Total Assets		19,747,935	12,579,626
LIABILITIES			
Current Liabilities			
Trade & other payables	9	15,671,654	8,629,286
Provision for employee benefits	10	308,289	315,599
Total Current Liabilities		<u>15,979,943</u>	<u>8,944,885</u>
Non-Current Liabilities			
Provision for employee benefits	10	6,748	3,307
Provision for office make good	10	180,000	180,000
Total Non-Current Liabilities		<u>186,748</u>	<u>183,307</u>
Total Liabilities		16,166,691	9,128,192
Net Assets		<u>3,581,244</u>	<u>3,451,434</u>
EQUITY			
General Funds		2,515,207	2,999,149
Research & Special Projects Reserves		1,066,037	452,285
Total Equity		<u>3,581,244</u>	<u>3,451,434</u>

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)
Statement of Changes in Equity
For the year ended 30 June 2016

	\$	\$	\$
	General Funds	Research & Special Projects Reserve	Total Funds
Balance at 1 July 2014	2,514,732	361,591	2,876,323
Transfer to/(from) reserves	(90,694)	90,694	-
Surplus after income tax for the year	575,111	-	575,111
Other Comprehensive income for the year, net of tax	-	-	-
Total comprehensive income for the year	575,111	-	575,111
Balance at 30 June 2015	2,999,149	452,285	3,451,434
Balance at 1 July 2015	2,999,149	452,285	3,451,434
Transfer to/(from) reserves	(613,752)	613,752	-
Surplus after income tax for the year	129,810	-	129,810
Other Comprehensive income for the year, net of tax	-	-	-
Total comprehensive income for the year	129,810	-	129,810
Balance at 30 June 2016	2,515,207	1,066,037	3,581,244

Cancer Council Australia (ABN 91 130 793 725)
Statement of Cash Flow
For the year ended 30 June 2016

	Note	<u>2016</u>	<u>2015</u>
		\$	\$
<u>Cash flows from operating activities:</u>			
Receipts from Member subscriptions, donations and other income (inclusive of GST)		18,238,381	11,020,845
Payments to suppliers, employees and Members (inclusive of GST)		(17,518,388)	(9,213,192)
Interest received		180,412	212,632
Net cash provided by operating activities	15	<u>900,405</u>	<u>2,020,285</u>
<u>Cash flows from investing activities:</u>			
Payments for term deposits		(29,701)	(4,214,339)
Payment for purchase of plant and equipment		(40,573)	(19,215)
Net cash used in investing activities		<u>(70,274)</u>	<u>(4,233,554)</u>
Net (decrease) / increase in cash & cash equivalents		830,131	(2,213,269)
Cash & cash equivalents at the beginning of the year		<u>3,617,313</u>	<u>5,830,582</u>
Cash & cash equivalents at the end of the year	5	<u>4,447,444</u>	<u>3,617,313</u>

The accompanying notes form part of these financial statements

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016

Note 1. Statement of significant accounting policies

Cancer Council Australia ("the Company") has adopted Australian Accounting Standards Reduced Disclosure Requirements as set out in AASB 1053. The financial statements are general purpose financial statements that have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements of the Australian Accounting Standards Board ("AASB") and the ACNC Act 2012.

The Company is a not-for-profit entity and incorporated Company limited by guarantee domiciled in Australia.

The financial report was authorised for issue by the Directors on 4 October 2016.

NEW, REVISED OR AMENDING ACCOUNTING STANDARDS AND INTERPRETATIONS ADOPTED

The Company has adopted all of the new, revised or amending Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new, revised or amending Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the Company.

The following Accounting Standards and Interpretations are most relevant to the Company:

- AASB 2012-3 Amendments to Australian Accounting Standards - Offsetting Financial Assets and Financial Liabilities
- AASB 2013-3 Amendments to AASB 136 - Recoverable Amount Disclosures for Non-Financial Assets
- AASB 2014-1 Amendments to Australian Accounting Standards (Parts A to C)

BASIS OF PREPARATION

These general purpose financial statements have been prepared in accordance with Australian Accounting Standards - Reduced Disclosure Requirements and Interpretations issued by the Australian Accounting Standards Board ('AASB'), Victorian legislation the Fundraising Appeals Act 1998 and associated regulations and the ACNC Act 2012, as appropriate for not-for-profit oriented entities.

REPORTING BASIS AND CONVENTIONS

The financial report has been prepared on an accruals basis (except as noted in 1 (d)(i)) and is based on historical costs and does not take into account changing money values or, except where specifically stated, current valuations of non-current assets. The following material accounting policies, which are consistent with the previous period have been adopted in the preparation of this report.

All amounts are in Australian dollars.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

ACCOUNTING POLICIES

(a) Plant & equipment

Plant and equipment is stated at historical cost less accumulated depreciation and impairment. Historical cost includes expenditure that is directly attributable to the acquisition of the items.

Depreciation

Depreciation is calculated on a straight-line basis to write off the net cost of each item of property, plant and equipment (excluding land) over their expected useful lives as follows:

<u>Class of plant and equipment</u>	<u>Useful Life</u>
Office Equipment	3 - 5 years
Computer Equipment	3 years
Leasehold Improvements	10 years

The residual values, useful lives and depreciation methods are reviewed, and adjusted if appropriate, at each reporting date.

An item of property, plant and equipment is derecognised upon disposal or when there is no future economic benefit to the Company. Gains and losses between the carrying amount and the disposal proceeds are taken to profit and loss.

Impairment of non-financial assets

Non-financial assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount.

Recoverable amount is the higher of an asset's fair value less cost of disposal and value-in-use. The value-in-use is the present value of the estimated future cash flows relating to the asset using a pre-tax discount rate specific to asset or cash-generating unit to which the asset belongs. Assets that do not have independent cash flows are grouped together to form a cash-generating unit.

(b) Provision for employee benefits

Short-term employee benefits

Liabilities for wages and salaries, including non-monetary benefits, annual leave and long service leave expected to be settled within 12 months of the reporting date are recognised in current liabilities in respect of employees' services up to the reporting date and are measured at the amounts expected to be paid when the liabilities are settled.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

Other long-term employee benefits

The liability for annual leave and long service leave not expected to be settled within 12 months of the reporting date are recognised in non-current liabilities, provided there is an unconditional right to defer settlement of the liability. The liability is measured as the present value of expected future payments to be made in respect of services provided by employees up to the reporting date using the projected unit credit method. Consideration is given to expected future wage and salary levels, experience of employee departures and periods of service. Expected future payments are discounted using market yields at the reporting date on national government bonds with terms to maturity and currency that match, as closely as possible, the estimated future cash outflows.

Defined contribution superannuation expense

Contributions to defined contribution superannuation plans are expensed in the period in which they are incurred.

(c) Leased assets

Lease payments for operating leases, where substantially all the risks and benefits remain with the lessor, are charged as expenses in the periods in which they are incurred.

(d) Revenue recognition

Revenue is recognised when it is probable that the economic benefit will flow to the Company and the revenue can be reliably measured. Revenue is measured at the fair value of the consideration received or receivable.

(i) Donations

The Company, in common with most organisations dependent upon contributions, is unable to establish absolute control over all voluntary donations, due to their nature, prior to their initial entry into the accounting records. Therefore, donations are recorded on the basis of cash received at the time the pledge is made. Donations received as a consequence of formalised national fund raising programs are recorded on a cash basis throughout the year and at year end are accrued to the extent that cash related to the pre year end event has subsequently been received.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(ii) Member organisation subscriptions and revenue forwarded to Members

Member subscription revenue is recognised on a basis that reflects the timing, nature and value of the benefits provided. Income from national events, donations and royalties is collected by the Company as an agent on behalf of state and territory Members and forwarded to Members on an annual basis.

	<u>2016</u>	<u>2015</u>
	\$	\$
The details of cash Members' subscriptions received during the year follow:		
Cash Member Subscriptions	<u>8,605,099</u>	<u>8,399,632</u>

The details of amounts received by the Company from national events, donations and royalties as an agent of state and territory Members follow:

Amounts forwarded to the Company's state and territory Members	<u>11,019,562</u>	<u>9,643,506</u>
--	-------------------	------------------

(iii) Grants

The Company receives grants to undertake certain projects. Where the grant is non reciprocal, it is recognised as revenue of the Company upon receipt. Associated expenditure for the completion of the grant is recorded as incurred. Where the grant is subject to a reciprocal transfer, a liability associated with the reciprocal transfer is recorded upon receipt of the grant. No income is recorded for reciprocal transfers until conditions associated with the grant are satisfied.

(iv) Royalties

Royalties are earned from the licensing of the use of the Company's endorsement on consumer products and are recorded on an accruals basis as advised by the licensee.

(v) Central Marketing Fund (CMF)

The Central Marketing Fund income received by the Company is contributed by product licensees for the implementation of campaigns to drive incremental sales of Cancer Council branded products and for key brand building activities. Such contributions received are subject to reciprocal transfer and are recorded as a liability upon receipt. Income is recorded when conditions/payments associated with the contributions are met.

(vi) Interest

Interest revenue is recognised as interest accrues using the effective interest method. This is a method of calculating the amortised cost of a financial asset and allocating the interest income over the relevant period using the effective interest rate, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to the net carrying amount of the financial asset.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(vii) Other revenue

Other revenue is recognised when it is received or when the right to receive payment is established.

(e) **Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is current when: it is expected to be realised or intended to be sold or consumed in normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within twelve months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. All other assets are classified as non-current.

A liability is current when: it is expected to be settled in normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within twelve months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period. All other liabilities are classified as non-current.

(f) **The William L. Rudder Memorial Fund**

A voluntary increment to the Company state/territory Members' subscriptions of 1% is directed to the William L. Rudder Memorial Fund. The subscriptions are collected by the Company on behalf of the William L. Rudder Memorial Fund.

(g) **Taxation**

The Company is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended, it is therefore exempt from income tax. This exemption has been confirmed by the Australian Taxation Office. The Company holds deductible gift recipient (DGR) status.

(h) **Cash & cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

(i) **Trade & other receivables**

Other receivables are recognised at amortised cost, less any provision for impairment.

(j) **Financial Instruments**

Initial recognition and measurement

Financial assets and financial liabilities are recognised when the entity becomes a party to the contractual provisions to the instrument. For financial assets, this is equivalent to the date that the entity commits itself to either the purchase or sale of the asset (ie trade date accounting is adopted).

Financial instruments are initially measured at fair value plus transaction costs, except where the instrument is classified "at fair value through profit or loss", in which case transaction costs are expensed to profit or loss immediately.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

Classification and subsequent measurement

Financial instruments are subsequently measured at fair value, amortised cost using the effective interest method, or cost.

Amortised cost is calculated as the amount at which the financial asset or financial liability is measured at initial recognition less principal repayments and any reduction for impairment, and adjusted for any cumulative amortisation of the difference between that initial amount and the maturity amount calculated using the effective interest method.

The effective interest method is used to allocate interest income or interest expense over the relevant period and is equivalent to the rate that discounts estimated future cash payments or receipts (including fees, transaction costs and other premiums or discounts) over the expected life (or when this cannot be reliably predicted, the contractual term) of the financial instrument to the net carrying amount of the financial asset or financial liability. Revisions to expected future net cash flows will necessitate an adjustment to the carrying amount with a consequential recognition of an income or expense item in profit or loss.

(k) Goods and Services Tax (GST)

Revenue, expenses and plant & equipment are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Tax Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of expense. Receivables and payables in balance sheet are shown inclusive of GST. Cash flows are presented in the cash flow statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

(l) Trade & other payables

These amounts represent liabilities for goods and services provided to the Company prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

(m) Comparative figures

Comparative figures of the Company for the previous 12 month period are included throughout these statements.

(n) Use of the term "surplus"

The Company is a not-for-profit organisation. As such, the term "profit" is not applicable and the term "surplus" is used where required.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(o) Critical accounting estimates and judgements

The Directors evaluate estimates and judgements incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Company.

The judgements, estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Estimation of useful lives of assets

The Company determines the estimated useful lives and related depreciation and amortisation charges for its plant and equipment. The depreciation and amortisation charge will increase where the useful lives are less than previously estimated lives, or technically obsolete. Leasehold improvements are depreciated over the term of the lease of the property.

Long service leave provision

The liability for long service leave is recognised and measured at the present value of the estimated future cash flows to be made in respect of all employees at the reporting date. In determining the present value of the liability, estimates of attrition rates and pay increases through promotion and inflation have been taken into account.

(p) National event merchandise ordered by the Company and recharged to Members

In the interests of its State and Territory Members, the Company designs and procures merchandise for national fundraising events. During the year, the Company aggregated orders from its Members and placed combined orders on the respective merchandise supplier(s) to ensure efficiencies and uniformity of buying. The costs for merchandise related to national fundraising events are recharged to the State and Territory Members as and when the merchandise is invoiced to the Company and subsequently delivered by the supplier(s) direct to the Members or elsewhere as agreed.

	<u>2016</u>	<u>2015</u>
	\$	\$
The costs of merchandise related to national fundraising events recharged to the state and territory Member organisations during the year totalled	<u>1,235,576</u>	<u>1,183,186</u>

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 1. Statement of significant accounting policies (cont'd)

(q) Provisions

Provisions are recognised when the Company has a present (legal or constructive) obligation as a result of a past event, it is probable the Company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting date, taking into account the risks and uncertainties surrounding the obligation. The make good provision represents the estimated costs to make good the premises leased by the Company at the end of the respective lease terms.

Note 2. Nature and Objects of the Company

The Company is an incorporated Company Limited by Guarantee under the *Corporations Act 2001*.

There were 8 Members of the Company at 30 June 2016.

The members (being the State and Territory Cancer Councils) undertake to contribute an amount not exceeding \$10 to the assets of the Company in the event of it being wound up.

The Company's Objects, given in the constitution are:

- (a) to foster national and international coordination and development of all activities in relation to cancer;
- (b) to promote the prevention of cancer in human beings;
- (c) to promote the control of cancer in human beings;
- (d) to provide relief for cancer patients and their families, including information, practical assistance, other support and advocacy services, and to engage in other benevolent activities relating to cancer; and to advocate for cancer patients and their families;
- (e) to promote public understanding and awareness of cancer, its causes and control, and the adoption by the community of measures to reduce the burden of cancer; and
- (f) to foster and support high quality cancer research in Australia.

As noted in the Directors' report, these Objects are currently under review as part of the broader view of the constitution.

Note 3. Economic dependence

The ability of the Company to maintain its operations is dependent, among other things, on the continuing support of the various State and Territory Members by way of Member subscriptions.

Cancer Council Australia (ABN 91 130 793 725)

Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 4. Revenue

	<u>2016</u>	<u>2015</u>
	\$	\$
<u>Revenue includes the following:</u>		
Membership Subscriptions (also refer to note 1 (d) (ii))	8,605,099	8,399,632
Interest Income	180,412	212,632
Central Marketing Fund income (also refer to note 1 (d) (v))	729,601	714,051
	<u>9,515,112</u>	<u>9,326,315</u>
<u>Other Revenue:</u>		
Grant Income	850,437	808,012
Events Income	409,885	372,121
Research & Special Projects	162,151	390,248
Other Revenue	474	2,538
	<u>1,422,947</u>	<u>1,572,919</u>
Total Income	<u>10,938,059</u>	<u>10,899,234</u>

Note 5. Cash & cash equivalents

Cash on hand	750	750
Cash at bank	4,446,694	3,616,563
	<u>4,447,444</u>	<u>3,617,313</u>

Note 6. Trade & other receivables

Current

Royalties receivable	395,509	720,786
Other amounts receivable	608,766	391,318
Amounts due from Member cancer organisations	8,540,728	2,015,366
Provision for Doubtful Debts	(31,700)	(41,700)
	<u>9,513,303</u>	<u>3,085,770</u>

Cancer Council Australia (ABN 91 130 793 725)**Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)****Note 7. Other current assets**

	<u>2016</u>	<u>2015</u>
	\$	\$
Held to maturity – term deposit	5,244,041	5,214,339
Prepayments	<u>59,515</u>	<u>92,846</u>
	<u>5,303,556</u>	<u>5,307,185</u>

Note 8. Plant & Equipment

Office Equipment		
- Office Equipment, at cost	374,058	367,886
- Accumulated depreciation	<u>(352,321)</u>	<u>(330,859)</u>
Total Office Equipment	<u>21,737</u>	<u>37,027</u>
Computer Equipment		
- Computer equipment, at cost	195,701	205,307
- Accumulated depreciation	<u>(171,170)</u>	<u>(158,182)</u>
Total Computer Equipment	<u>24,531</u>	<u>47,125</u>
Leasehold Improvements		
- Leasehold improvements, at cost	694,666	673,159
- Accumulated depreciation	<u>(257,302)</u>	<u>(187,953)</u>
Total Leasehold Improvements	<u>437,364</u>	<u>485,206</u>
Total Plant & Equipment	<u>483,632</u>	<u>569,358</u>

The net surplus has been determined after charging the following specific expense:

Depreciation of plant & equipment	<u>126,299</u>	<u>178,814</u>
-----------------------------------	----------------	----------------

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 8. Plant & equipment (cont'd)

	Office Equipment \$	Computer Equipment \$	Leasehold Improvements \$	Total \$
Balance at 1 July 2014	79,498	63,937	405,522	548,957
Additions	-	19,215	180,000	199,215
Depreciation expense	(42,471)	(36,027)	(100,316)	(178,814)
Balance at 30 June 2015	37,027	47,125	485,206	569,358
Additions	6,172	12,894	21,507	40,573
Depreciation expense	(21,462)	(35,488)	(69,349)	(126,299)
Balance at 30 June 2016	21,737	24,531	437,364	483,632

Note 9. Trade & other payables

	2016 \$	2015 \$
<u>Current</u>		
Trade creditors	2,578,231	2,706,632
Sundry creditors	722,538	880,705
Income in advance – grants & events	1,084,463	768,933
Income in advance - other	72,759	49,824
Amounts due to Members	11,213,663	4,223,192
	<u>15,671,654</u>	<u>8,629,286</u>

Note 10. Provisions

<u>Current:</u>		
Employee benefits	308,289	315,599
	<u>308,289</u>	<u>315,599</u>
<u>Non-Current:</u>		
Employee benefits	6,748	3,307
Office lease make good	180,000	180,000
	<u>186,748</u>	<u>183,307</u>
<u>Office lease make good</u>		
Carrying amount at the start of the year	180,000	-
Additional provisions recognised	-	180,000
Amounts used	-	-
Carrying amount at the end of the year	<u>180,000</u>	<u>180,000</u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 11. Commitments

	2016	2015
	\$	\$
<u>Non-cancellable operating lease commitments</u>		
Non-cancellable operating leases contracted but not capitalised in the financial statements:		
<u>Payable</u>		
Not longer than one year	400,425	381,239
Longer than one year but not longer than five years	1,780,906	1,705,665
Longer than five years but not longer than ten years	583,407	1,059,073
	<u>2,764,738</u>	<u>3,145,977</u>
The net surplus has been determined after charging the following specific expense:		
Rental expense – minimum lease payments	<u>369,525</u>	<u>350,796</u>
<u>Priority-Driven Research Grant Commitments</u>		
Commitments contracted for, but not recognised as liabilities at the balance date, and expected to be funded from annual subscription fees from Members:		
<u>Payable</u>		
Not longer than one year	402,000	299,241
Longer than one year but not longer than five years	54,667	223,360
	<u>456,667</u>	<u>522,601</u>

Note 12. Key management personnel disclosures

Compensation

The aggregate compensation made to Directors and key management personnel of the Company is set out below:

2016	2015
\$	\$
<u>916,420</u>	<u>946,585</u>

Note 13. Contingent liabilities

There are no contingent liabilities as at the end of the year other than those identified elsewhere in the report.

	2016	2015
	\$	\$
Bank guarantee in respect of operating leases	<u>179,684</u>	<u>179,684</u>

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 14. Events subsequent to reporting date

The Directors are not aware of any significant events have occurred since the end of the reporting period which would impact on the financial position of the Company disclosed in the balance sheet as at 30 June 2016 or on the results and cash flows of the Company for the year ended on that date.

Note 15. Reconciliation of cash flows from operating activities with net surplus for the year

	2016	2015
	\$	\$
Net surplus for the year	129,810	575,111
Non-cash flows in net surplus for the year:		
Depreciation	126,299	178,814
Changes in assets and liabilities:		
Increase in receivables	(6,427,533)	(2,112,645)
(Increase) / decrease in other assets	33,330	(18,491)
Decrease in provisions	(3,869)	(141,504)
Increase in payables	<u>7,042,368</u>	<u>3,539,000</u>
Net cash provided by operating activities	<u>900,405</u>	<u>2,020,285</u>

Note 16. Remuneration of the Auditor

During the year, the following fees were paid or payable for services provided by the Auditor, BDO East Coast Partnership to the Company:

	2016	2015
	\$	\$
External audit of the financial statement	<u>22,600</u>	<u>22,200</u>

Note 17. Company Details

The registered office and principal place of business of the Company is:

Level 14, 477 Pitt Street
 Sydney NSW 2000 Australia

The Company operates entirely in Australia as a Health Promotion Charity.

Cancer Council Australia (ABN 91 130 793 725)
Notes to the Financial Statements for the year ended 30 June 2016 (cont'd)

Note 18. Related party transactions

Key management personnel

Disclosures relating to key management personnel are set out in note 12.

Transactions with related parties

The only related parties were the Members and that there were no related party transactions other than those already disclosed during the current and previous financial year.

Receivable from and payable to related parties

Other than those already disclosed, there were no trade receivables from or trade payables to related parties at the current and previous reporting date.

Loans to/from related parties

There were no loans to or from related parties at the current and previous reporting date.

Cancer Council Australia (ABN 91 130 793 725)
Financial report for the year ended 30 June 2016
Directors' Declaration


In the Directors' opinion:

1. The attached financial statements and notes comply with the ACNC Act 2012, Australian Accounting Standards – Reduced Disclosure Requirements, the ACNC Regulations 2013 and other mandatory professional reporting requirements;
2. The attached financial statements and notes thereto give a true and fair view of the Company's financial position as at 30 June 2016 and of its performance for the financial year ended on that date; and
3. There are reasonable grounds to believe that the Company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the Directors by:



The Hon. Nicola Roxon
Chair



Mr Hugh Harley
Director

Sydney
4 October 2016



Tel: +61 2 9251 4100
Fax: +61 2 9240 9821
www.bdo.com.au

Level 11, 1 Margaret St
Sydney NSW 2000
Australia

INDEPENDENT AUDITOR'S REPORT

To the members of Cancer Council Australia

Report on the Financial Report

We have audited the accompanying financial report of Cancer Council Australia, which comprises the statement of financial position as at 30 June 2016, the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors declaration.

Directors' Responsibility for the Financial Report

The directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Australian Charities and Not-for-profits Commission Act 2012 (ACNC Act)* and for such internal control as the directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on the financial report based on our audit. We conducted our audit in accordance with Australian Auditing Standards. Those standards require that we comply with relevant ethical requirements relating to audit engagements and plan and perform the audit to obtain reasonable assurance about whether the financial report is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial report. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial report, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the company's preparation of the financial report that gives a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the directors, as well as evaluating the overall presentation of the financial report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



Opinion

In our opinion, the financial report of Cancer Council Australia has been prepared in accordance with Division 60 of the *Australian Charities and Not-for-profits Commission Act 2012*, including:

- (a) giving a true and fair view of the company's financial position as at 30 June 2016 and of its financial performance and cash flows for the year ended on that date; and
- (b) complying with Australian Accounting Standards and Division 60 of the *Australian Charities and Not-for-profits Commission Regulation 2013*.

BDO East Coast Partnership

A handwritten signature in blue ink that reads 'BDO'.

A handwritten signature in blue ink that reads 'Paul Cheeseman'.

Paul Cheeseman
Partner

Sydney, 4 October 2016